Insidensi dan Karakteristik Karsinoma Hepatoseluler di RSUD Abdul Wahab Sjahranie Samarinda
Keywords:
Karsinoma hepatoseluler, insidensi, karakteristik, survival rateAbstract
References
[1] Globocan 2018, “Liver Cancer Global WHO Report,” Iarc, vol. 876, pp. 2018–2019, 2018, [Online]. Available: http://gco.iarc.fr/today.
[2] World Health Organization, “Indonesia Source GLOBOCAN 2018,” Int. Agency Res. Cancer, vol. 256, pp. 1–2, 2019, [Online]. Available: http://gco.iarc.fr/.
[3] W. Desen and W. Japaries, Buku Ajar Onkologi Klinis Edisi 2. Jakarta: FKUI, 2013.
[4] J. A. Marrero et al., “Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases,” Hepatology, vol. 68, no. 2, pp. 723–750, 2018, doi: 10.1002/hep.29913.
[5] I. M. Loho, L. Siregar, A. S. Waspodo, and I. Hasan, “Current Practice of Hepatocellular Carcinoma Surveillance,” Acta Med. Indones., vol. 50, no. 4, pp. 353–360, 2018.
[6] R. A. Gani, M. Suryamin, I. Hasan, C. R. A. Lesmana, and A. Sanityoso, “Performance of Alpha Fetoprotein in Combination with Alpha-1-acid Glycoprotein for Diagnosis of Hepatocellular Carcinoma Among Liver Cirrhosis Patients,” Acta Med. Indones., vol. 47, no. 3, pp. 216–222, 2015.
[7] A. Kinoshita, H. Onoda, N. Fushiya, K. Koike, H. Nishino, and H. Tajiri, “Staging systems for hepatocellular carcinoma: Current status and future perspectives,” World J. Hepatol., vol. 7, no. 3, pp. 406–424, 2015, doi: 10.4254/wjh.v7.i3.406.
[8] Tim Riskesdas 2018, Laporan Provinsi Kalimantan Timur Riskesdas 2018. Jakarta: Lembaga Penerbit Badan Penelitian dan Pengembangan Kesehatan, 2019.
[9] S. H. Oktavia, “Profil dan Faktor Risiko Penderita Karsinoma Hepatoseluler di RSUP Haji Adam Malik Medan Tahun 2016 – 2017,” 2017.
[10]M. RP and H. Hardian, “Distribusi Geografis Dan Tingkat Keparahan Pasien Karsinoma Hepatoseleluler Etiologi Virus Hepatitis B Di Rs.Dr Kariadi,” J. Kedokt. Diponegoro, vol. 5, no. 4, pp. 1291–1302, 2016.
[11]M. Montella et al., “Role of Sex Hormones in the Development and Progression of Hepatitis B Virus-Associated Hepatocellular Carcinoma,” Int. J. Endocrinol., vol. 2015, 2015, doi: 10.1155/2015/854530.
[12]A. Aljumah et al., “Clinical presentation and risk factors of hepatocellular carcinoma in saudi arabia: A tertiary care center experience,” Saudi J. Gastroenterol., vol. 22 (7 Supp, p. S1, 2016, [Online]. Available: https://uhn.idm.oclc.org/login?url=http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emexb&AN=627782179http://nt2yt7px7u.search.serialssolutions.com/?sid=OVID:Embase&genre=article&id=pmid:&id=doi:&issn=1998-4049&volume=22&issue=7+Suppl.
[13]U. Budihusodo, Buku Ajar Ilmu Penyakit Hati. Jakarta: Sagung Seto, 2012.
[14]Hasan I et al., “Risk Factors for Hepatocellular Carcinoma and Its Mortality Rate : A Multicenter Study in Indonesia,” Arch. Cancer Res., vol. 7, pp. 1–7, 2019, doi: 10.21767/2254-6081.100191.
[15]I. Ayuningtyas and H. D. Purnomo, “Karakteristik Klinis Pasien Karsinoma Hepatoseluler: Studi Kasus Di Rsup Dr Kariadi Semarang Periode 2010-2012,” pp. 38–44, 2014, [Online]. Available: http://eprints.undip.ac.id/44757/.
[16]Muslimah Derajatun Rizki, “PROFIL KEJADIAN KARSINOMA HEPATOSELULER DI RUMAH SAKIT UMUM DAERAH Dr. MOEWARDI TAHUN 2017,” 2018.
[17]M. Mohammadian, N. Mahdavifar, A. Mohammadian-Hafshejani, and H. Salehiniya, “Liver cancer in the world: epidemiology, incidence, mortality and risk factors,” World cancer Res. J., vol. 5, no. 2, p. e1082, 2018, [Online]. Available: https://www.wcrj.net/wp-content/uploads/sites/5/2018/06/e1082-Liver-cancer-in-the-world-Epidemiology-incidence-mortality-and-risk-factors.pdf.
[18]K. K. RI, “Infodatin Situasi Penyakit Hepatitis B di Indonesia Tahun 2017,” Pus. Data dan Inf., p. 6, 2017, doi: 10.1017/CBO9781107415324.004.
[19]N. S. A. Gumilas, I. M. Harini, T. Sylviningrum, W. Djatmiko, and L. Rujito, “Hepatitis B as hepatocellular carcinoma (HCC) risk factor in the south region of Java, Indonesia,” J. Phys. Conf. Ser., vol. 1246, no. 1, 2019, doi: 10.1088/1742-6596/1246/1/012013.
[20]S. Pascual, I. Herrera, and J. Irurzun, “New advances in hepatocellular carcinoma,” World J. Hepatol., vol. 8, no. 9, pp. 421–438, 2016, doi: 10.4254/wjh.v8.i9.421.
[21] “infodatin-hepatitis 1.pdf.” .
[22]P. Rawla, T. Sunkara, P. Muralidharan, and J. P. Raj, “Update in global trends and aetiology of hepatocellular carcinoma,” Wspolczesna Onkol., vol. 22, no. 3, pp. 141–150, 2018, doi: 10.5114/wo.2018.78941.
[23]A. J. Sanyal, S. K. Yoon, and R. Lencioni, “The Etiology of Hepatocellular Carcinoma and Consequences for Treatment,” Oncologist, vol. 15, no. S4, pp. 14–22, 2010, doi: 10.1634/theoncologist.2010-s4-14.
[24]P. Ramadori, F. J. Cubero, C. Liedtke, C. Trautwein, and Y. A. Nevzorova, “Alcohol and hepatocellular carcinoma: Adding fuel to the flame,” Cancers (Basel)., vol. 9, no. 10, pp. 1–22, 2017, doi: 10.3390/cancers9100130.
[25]E. S. Jang, S. H. Jeong, J. W. Kim, Y. S. Choi, P. Leissner, and C. Brechot, “Diagnostic performance of alpha-fetoprotein, protein induced by Vitamin K absence, osteopontin, Dickkopf-1 and its combinations for hepatocellular carcinoma,” PLoS One, vol. 11, no. 3, 2016, doi: 10.1371/journal.pone.0151069.
[26]Y. Peng, X. Qi, and X. Guo, “Child-pugh versus MELD score for the assessment of prognosis in liver cirrhosis a systematic review and meta-analysis of observational studies,” Med. (United States), vol. 95, no. 8, pp. 1–29, 2016, doi: 10.1097/MD.0000000000002877.
[27]C. Y. Wang and S. Li, “Clinical characteristics and prognosis of 2887 patients with hepatocellular carcinoma: A single center 14 years experience from China,” Medicine (Baltimore)., vol. 98, no. 4, p. e14070, 2019, doi: 10.1097/MD.0000000000014070.
Downloads
Published
Issue
Section
How to Cite
Most read articles by the same author(s)
- Hurria Maulana Ali, Annisa Muhyi, Yudanti Riastiti, Hubungan Usia, Kadar Hemoglobin Pretransfusi dan Lama Sakit terhadap Kualitas Hidup Anak Talasemia di Samarinda , Jurnal Sains dan Kesehatan: Vol. 3 No. 4 (2021): J. Sains Kes.
- Muhammad Rizky Ramadhan, Yuliana Rahmah Retnaningrum, Yudanti Riastiti, Yadi Yadi, Hadi Irawiraman, Pengaruh Konsumsi Pisang Ambon (Musa paradisiaca) terhadap Penurunan Tekanan Darah Penderita Hipertensi di Puskesmas Bontang Selatan , Jurnal Sains dan Kesehatan: Vol. 3 No. 2 (2021): J. Sains Kes.